0.32
0.32 (-0.65%)
As of Feb 12, 2024
Invivo Therapeutics Holdings Corp. [NVIV]
Source:
Company Overview
Invivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries, or SCIs. Our mission is to redefine the life of the SCI patient.
| Country | United States |
| Headquarters | cambridge, massachusetts |
| Phone Number | 617-863-5524 |
| Industry | manufacturing |
| CEO | Richard Toselli |
| Website | www.invivotherapeutics.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | |
| Operating Profit | $-2.8 |
| Net Income | $-2.7 |
| Net Cash | $-7.9 |
Profit Ratios
| Gross Margin | |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -19% |
| Profit as % of Stockholder Equity | -30.2% |
Management Effectiveness
| Return on Equity | -30.2% |
| Return on Assets | -28.1% |
| Turnover Ratio | |
| EBITA |
Balance Sheet and Cash Flow Measures
| Total Assets | $9.6 |
| Total Liabilities | $0.7 |
| Operating Cash Flow | $-7.9 |
| Investing Cash Flow | $0.1 |
| Financing Cash Flow |
